2025 ASCO前瞻｜肺癌Oral「三大研究趋势」抢先看，中国专家领衔7项研究

2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。本次ASCO年会共收录了17项肺癌领域口头报告（Oral），涵盖转移性/局部晚期/局限期非小细胞肺癌（NSCLC）及小细胞肺癌（SCLC）各治疗阶段的研究。其中，中国研究团队共主导或深度参与7项Oral研究，包括5项转移性NSCLC（CAMPASS、Oral报告、SACHI、HERTHENA-Lung02、OptiTROP-Lung03）、1项局部晚期/局限期NSCLC（R-ALPS）以及1项SCLC（ZG006）相关研究，体现出中国在肺癌临床研究中的活跃地位与国际影响力不断上升。

本届ASCO肺癌研究呈现三大特点：精准治疗持续深化，如针对KRAS G12C、EGFR、HER2、MET等多种靶点的新一代药物和抗体偶联药物频频亮相；免疫联合策略拓展边界，如免疫+抗血管、免疫+抗体偶联药物、免疫+SBRT等新组合探索；围手术期治疗地位进一步确立，CheckMate 816、NeoADAURA等研究强调新辅助/辅助治疗延长总生存。整体趋势显示，肺癌治疗正向“分子精准+免疫整合+早期干预”方向加速发展，中国研究者正在多条赛道实现创新行突破，并与全球接轨。【ONCO前沿】特整理肺癌领域最新Oral摘要题目等相关信息，让我们一同揭晓！

中文标题：II期KRYSTAL-7研究：adagrasib（ADA）联合帕博利珠单抗（PEMBRO）联合治疗晚期/转移性KRASG12C突变型非小细胞肺癌（NSCLC）患者。

英文标题：First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

讲者：Pasi A. Jänne, PhD | Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

中文标题：TROPION-Lung02：Datopotamab deruxtecan（Dato-DXd）联合帕博利珠单抗（pembro）联合或不联合铂类化疗（Pt-CT）一线治疗晚期非小细胞肺癌（aNSCLC）。

英文标题：TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).

讲者：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine

中文标题：CAMPASS研究：在晚期非小细胞肺癌（aNSCLC）的一线治疗中，贝莫苏拜单抗联合安罗替尼 vs 帕博利珠单抗的一项随机、单盲、多中心3期研究。

英文标题：CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study.

讲者：韩宝惠教授｜上海市胸科医院

中文标题：Zipalertinib对既往接受过铂类化疗±amivantamab的EGFR 20外显子插入突变NSCLC患者的疗效。

英文标题：Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

讲者：Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center

中文标题：SOHO-01：探索BAY 2927088用于既往接受过 HER2 靶向治疗但对 HER2 靶向治疗不敏感或未接受过任何治疗的晚期 HER2 突变非小细胞肺癌（NSCLC）患者的安全性和有效性。

英文标题：SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.

讲者：Herbert H. Loong教授｜香港中文大学

中文标题：随机III期SACHI研究结果：Savolitinib（Savo）联合奥希替尼（Osi）对比化疗（Chemo）用于EGFR突变（EGFRm）合并MET扩增（METamp）晚期NSCLC且在EGFR TKI治疗后进展患者的疗效

英文标题：Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

讲者：陆舜教授 | 上海胸科医院

中文标题：III期HERTHENA-Lung02研究：Patritumab deruxtecan（HER3-DXd）治疗三代EGFR TKI耐药后的EGFR突变（EGFRm）晚期NSCLC

英文标题：Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

讲者：莫树锦教授｜香港中文大学

中文标题：随机OptiTROP-Lung03研究结果：Sacituzumab tirumotecan（sac-TMT）用于既往接受过治疗的EGFR突变晚期NSCLC患者

英文标题：Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.

讲者：张力教授｜中山大学肿瘤防治中心

中文标题：CheckMate 816研究：纳武利尤单抗（NIVO）联合化疗新辅助治疗可切除NSCLC患者的总生存期分析

英文标题：Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.

讲者：Patrick M. Forde, MD, PhD | Trinity St. James's Cancer Institute, Trinity College Dublin

中文标题：NeoADAURA研究：奥希替尼（Osi）± 化疗（CT）vs 单独化疗新辅助治疗可切除EGFR突变NSCLC患者

英文标题：Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.

讲者：Jamie E. Chaft, MD, FASCO | Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College

中文标题：密西西比三角洲地区肺癌筛查（LCS）与偶发性肺结节（IPN）人群中的肺癌诊断率（LCDR）

英文标题：Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.

讲者：Raymond U. Osarogiagbon, MBBS, FACP, FASCO | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Program

中文标题：SWOG/NRG S1914：阿替利珠单抗联合SBRT vs 单独SBRT诱导/巩固治疗高风险、早期NSCLC患者的III期随机试验

英文标题：SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.

讲者：Megan Eileen Daly, MD | Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center

中文标题：R-ALPS研究：TQB2450±安罗替尼用于未进展的局部晚期、不可切除（III期）NSCLC患者的维持治疗：III期双盲安慰剂对照多中心临床试验

英文标题：R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.

讲者：陈明教授｜中山大学肿瘤防治中心

中文标题：放化疗（CRT）后使用阿替利珠单抗是否能延长局限期（LS）小细胞肺癌（SCLC）患者生存期的随机II期研究

英文标题：Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).

讲者：Bjorn Henning Gronberg, MD, PhD | Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology and Department of Oncology, St. Olavs Hospital